Company Overview

---

CEO & Chairman of the Board

Dr. Maida is a scientific icon in the clinical development of immunotherapies to treat patients with cancer. He has served in several executive roles, including, Chairman, CEO, COO, CSO, CFO, and business development.  Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc., focused on cancer immunotherapy and infectious disease programs. He is a member of the American Society of Clinical Oncology (“ASCO”), the American Association for Cancer Research (“AACR”), the Society of Neuro-Oncology (“SNO”), the International Society for Biological Therapy of Cancer (“iSBTc”) and the American Chemical Society (“ACS”).

Board Member

William L. Ashton is a former Fortune 100 senior executive with over 30 years’ experience in the biotechnology and pharmaceutical business.  Mr. Ashton retired from a lengthy career at Amgen Inc., the world's largest biotechnology firm. Following his retirement from Amgen, Mr. Ashton joined the University of Sciences in Philadelphia (formerly the Philadelphia College of Pharmacy and Science).  There he served in various roles including the Dean of the Mayes College of Healthcare Business and Policy, and as Assistant Professor of Healthcare Business.  Later he served as the Senior Vice President of External Affairs reporting to the President of the University.  Since the beginning of 2013, Mr. Ashton has been a principal at Harrison Consulting Group, LLC, a privately held biopharmaceutical consulting firm with expertise in commercialization, payer strategy, and reimbursement.

Chair of Scientific Advisory Board

Dr. Lam is recognized as one of the pioneers who started the field of synthetic combinatorial chemistry. In the last 15 years, Dr. Lam has expanded his research program into nanomedicine.  In 2022, Dr. Lam published data on the novel nano immuno-engager (“NIE”) platform that transforms into nanofibriles at the tumor sites, resulting in the conversion of an immunological “cold tumor” to “hot tumor,” with this research creating the scientific foundation for the formation of T-NanoBio Therapeutics, Inc. Dr Lam has been serving in the last 20 years as the co-director of the Cancer Therapeutic Program of UC Davis NCI-designated Comprehensive Cancer Center.   

Board Member

Richard Slansky is a senior financial executive with more than 30 years of experience as Chief Financial Officer in various biopharmaceutical, diagnostic, and life science companies, including Genenta, Oncosec, Biological Dynamics and Genmark Diagnostics. His experience spans public and private companies, pre-revenue to revenue growth, and commercial healthcare and high technology environments. He has been responsible for strategic vision and oversight of financial and operational teams, organizational leadership and creating maximum stakeholder value. He also serves on the Board of Directors of several private companies, including Nuclear RNA Networks, an early-stage RNA gene transcription therapeutics company.

Board Member

Dr. Welles has a combined 30 years of experience in drug development and life science investing.  She is board certified in Internal Medicine and Endocrinology and Metabolism.  After a brief academic career at the University of California, San Francisco, where she performed basic research in lipoprotein metabolism, Dr. Welles spent a decade at Genentech where she performed clinical research across multiple therapeutic areas and across all phases of development. There she took on increasing levels of responsibility, and ultimately was Vice President of Product Development, responsible for oversight of all pipeline projects, Portfolio Management, and Project Management. Dr. Welles had direct responsibility for the filing of 6 INDs and 2 NDAs and was Team Leader for Lucentis, which achieved global sales of greater than $3 billion in 2023.  After her departure from Genentech, Dr. Welles served as a Venture Partner with MPM Capital, a life science fund with $1 billion under management, where she led several investments and assisted portfolio companies with their development programs and interactions with the Food and Drug Administration.  Since 2012, she has been Managing Director with IPF Partners, a European investment fund dedicated to providing growth capital to emerging healthcare companies.  Dr. Welles received a certificate in Corporate Governance at the UCLA Anderson School of Management.  She has served as a director in both listed and private biotechnology companies and also served on the Board of Directors of the San Francisco Food Bank.